{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:50Z","timestamp":1792718330143,"version":"4.5.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The limited therapeutic options and inconsistent treatment efficacy of Intestinal Beh\u00e7et\u2019s disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>In this case report, we present a patient with refractory intestinal Beh\u00e7et\u2019s disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Beh\u00e7et\u2019s disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1483993","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:25Z","timestamp":1731046225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Beh\u00e7et\u2019s disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Sumei","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.disamonth.2023.101674","article-title":"Gastrointestinal Behcet's disease: Manifestations, diagnosis, and management","volume":"70","author":"Manuelyan","year":"2024","journal-title":"Dis Mon"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8176","DOI":"10.3390\/ijms24098176","article-title":"Intestinal behcet's disease: A review of the immune mechanism and present and potential biological agents","volume":"24","author":"He","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5009\/gnl17462","article-title":"Anti-tumor necrosis factor therapy in intestinal behcet's disease","volume":"12","author":"Park","year":"2018","journal-title":"Gut Liver"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12876-022-02221-0","article-title":"Efficacy and predictor of anti-TNFalpha agents in patients with intestinal Behcet's disease","volume":"22","author":"Miyazaki","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.394","article-title":"Real-world effectiveness\u00a0and safety of adalimumab in Korean patients with intestinal Behcet\u2019s\u00a0disease: a Korean Association for the Study of Intestinal Diseases (KASID)\u00a0multicenter study","volume":"38","author":"Lee","year":"2023","journal-title":"Korean J Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Behcet's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1759720X221124014","DOI":"10.1177\/1759720X221124014","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Behcet's syndrome","volume":"14","author":"Zou","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.v12.4","article-title":"Coexistence of ankylosing spondylitis and Behcet's disease: Successful treatment with upadacitinib","volume":"12","author":"Kraev","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with behcet's uveitis","volume":"32","author":"Tao","year":"2023","journal-title":"Ocul Immunol Inflammation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmeister","year":"2023","journal-title":"RMD Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1483993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:27Z","timestamp":1731046227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1483993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2024.1483993"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1483993","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"article-number":"1483993"}}